PriceTargets.com logo

Metsera - MTSR Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $47.00
  • Forecasted Upside: 137.25%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$19.81 As of 04/28/2025 05:00 PM ET
▲ +1.28 (6.91%)

This chart shows the closing price for MTSR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
MarApr$19.81Closing price on 04/28/25:
Get New Metsera Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MTSR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MTSR

Analyst Price Target is $47.00
▲ +137.25% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Metsera in the last 3 months. The average price target is $47.00, with a high forecast of $56.00 and a low forecast of $38.00. The average price target represents a 137.25% upside from the last price of $19.81.

This chart shows the closing price for MTSR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
2/254/255/26$9.16$21$33$44$56Closing price on 04/28/25: $19.81High$56.00Average$47.00Low$38.00




Current Consensus is Buy

The current consensus among 4 contributing investment analysts is to buy stock in Metsera.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/5/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/3/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/3/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/1/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/30/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/28/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/29/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/28/2025

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
2/25/2025Cantor FitzgeraldInitiated CoverageOverweight
2/25/2025GuggenheimInitiated CoverageBuy$56.00
2/25/2025Bank of AmericaInitiated CoverageBuy$38.00
2/25/2025Evercore ISIInitiated CoverageOutperform
(Data available from 4/28/2020 forward)

News Sentiment Rating

0.18 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/30/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/30/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/29/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/29/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/28/2025
  • 2 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/27/2025
  • 7 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
3/29/2025
  • 1 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
4/28/2025

Current Sentiment

  • 1 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Metsera logo
Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.
Read More

Today's Range

Now: $19.81
Low: $18.45
High: $20.26

50 Day Range

MA: $23.57
Low: $13.08
High: $31.68

52 Week Range

Now: $19.81
Low: $12.30
High: $32.81

Volume

522,613 shs

Average Volume

876,332 shs

Market Capitalization

$2.08 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Metsera?

The following sell-side analysts have issued reports on Metsera in the last twelve months: Bank of America Co., Cantor Fitzgerald, Evercore ISI, and Guggenheim.
View the latest analyst ratings for MTSR.

What is the current price target for Metsera?

0 Wall Street analysts have set twelve-month price targets for Metsera in the last year. Their average twelve-month price target is $47.00, suggesting a possible upside of 137.3%. Guggenheim has the highest price target set, predicting MTSR will reach $56.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $38.00 for Metsera in the next year.
View the latest price targets for MTSR.

What is the current consensus analyst rating for Metsera?

Metsera currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MTSR will outperform the market and that investors should add to their positions of Metsera.
View the latest ratings for MTSR.

What other companies compete with Metsera?

Other companies that are similar to Metsera include Revolution Medicines, Lantheus, BridgeBio Pharma, TG Therapeutics and Telix Pharmaceuticals Limited American Depositary Shares. Learn More about companies similar to Metsera.

How do I contact Metsera's investor relations team?

Metsera's physical mailing address is 3 WORLD TRADE CENTER, 175 GREENWICH STREET, NEW YORK, NY, 10007. The company's listed phone number is (212) 784-6595 and its investor relations email address is investors@metsera.com. The official website for Metsera is metsera.com. Learn More about contacing Metsera investor relations.